What changed from existing technology?
This study tested a new way to treat advanced stomach cancer before surgery by delivering chemotherapy directly into the arteries and blocking blood flow to the tumor. It showed that this method can shrink tumors in many patients and may help prevent cancer from coming back.
This is the first study to evaluate transarterial infusion chemotherapy and embolization as a neoadjuvant therapy for gastric cancer, demonstrating its potential as a new pre-operative treatment approach.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 1
d explored its potential anti-tumor mechanisms. Twenty patients were enrolled in this study. The pathological complete response (pCR) and major pathological r
Abstract ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Near commercialization
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
This approach may be considered for patients with locally advanced gastric cancer who are candidates for surgery, though further studies are needed to confirm its long-term benefits and optimal application.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.